• Home

  • Documents

  • AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to...
38

AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa

  • Upload
    others

  • View
    3

  • Download
    0

Embed Size (px)

Citation preview

Page 1: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 2: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 3: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 4: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 5: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 6: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 7: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 8: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 9: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 10: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 11: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 12: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 13: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 14: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 15: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 16: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 17: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 18: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 19: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 20: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 21: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 22: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 23: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 24: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 25: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 26: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 27: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 28: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 29: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 30: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 31: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 32: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 33: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 34: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 35: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 36: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 37: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa
Page 38: AkL— Erk Akt by gelilinib; Acme, of or Akt mutated, Deg. deletion.—SPTEN pnfein relative to 11460, the Weslan BIN data in Figure 2. tuxrnalized 10 Il-actin. EGFR o CTL 60 Iressa

AKT preparation

AKT preparation

Documents
A Circular RNA Binds To and Activates AKT Phosphorylation ...The AKT pathway is highly regulated, starting by activation of PI3K and AKT 7. Normally, AKT resides in the cytoplasm as

A Circular RNA Binds To and Activates AKT Phosphorylation ...The AKT pathway is highly regulated, starting by activation of PI3K and AKT 7. Normally, AKT resides in the cytoplasm as

Documents
AKT as a Therapeutic Target for Cancer · AKT and also provide details regarding synthetic and natural AKT-targeting compounds and their associated studies. Introduction The AKT serine/threonine

AKT as a Therapeutic Target for Cancer · AKT and also provide details regarding synthetic and natural AKT-targeting compounds and their associated studies. Introduction The AKT serine/threonine

Documents
AKT 125 EVO

AKT 125 EVO

Documents
Diabetes for the AKT

Diabetes for the AKT

Documents
employee - AKT

employee - AKT

Documents
Konservatisme akt

Konservatisme akt

Documents
Metastasis and AKT activation

Metastasis and AKT activation

Documents
7 PI3K/Akt

7 PI3K/Akt

Documents
PI3K, AKT, and P-AKT levels in thin endometrium · 2018. 5. 10. · PI3K, AKT and P-AKT in thin endometrium 3 Genetics and Molecular Research 15 (1): gmr.15017184 FUNPEC-RP within

PI3K, AKT, and P-AKT levels in thin endometrium · 2018. 5. 10. · PI3K, AKT and P-AKT in thin endometrium 3 Genetics and Molecular Research 15 (1): gmr.15017184 FUNPEC-RP within

Documents
Preparing for AKT

Preparing for AKT

Documents
AKT and Apoptosis

AKT and Apoptosis

Documents
Enhanced Efficacy With Iressa (Ahmad Hudoyo)

Enhanced Efficacy With Iressa (Ahmad Hudoyo)

Documents
SE NOAA Chart 11460

SE NOAA Chart 11460

Documents
21-399 IRESSA Medical Review Part 1 · 2009-04-21 · Title: 21-399 IRESSA Medical Review Part 1 Created Date: 7/1/2003 2:27:57 PM

21-399 IRESSA Medical Review Part 1 · 2009-04-21 · Title: 21-399 IRESSA Medical Review Part 1 Created Date: 7/1/2003 2:27:57 PM

Documents
Efficacy Claims and Subset Analyses in Phase III: Some ... · IPASS: Phase III study of IRESSA versus doublet chemotherapy in first line NSCLC IRESSA 250 mg/day. Carboplatin AUC 5

Efficacy Claims and Subset Analyses in Phase III: Some ... · IPASS: Phase III study of IRESSA versus doublet chemotherapy in first line NSCLC IRESSA 250 mg/day. Carboplatin AUC 5

Documents
AKT LLC tariffnta.nv.gov/uploadedFiles/ntanvgov/content/Carriers/Tariffs/Tar_-_A_to_C/AKT_LLC_2261...AKT, LLC., d/b/a AKT Charter Service Tariff I . APPLICATION OF CARRIERS OPERA TING

AKT LLC tariffnta.nv.gov/uploadedFiles/ntanvgov/content/Carriers/Tariffs/Tar_-_A_to_C/AKT_LLC_2261...AKT, LLC., d/b/a AKT Charter Service Tariff I . APPLICATION OF CARRIERS OPERA TING

Documents
Akt. 252627 Zadatak

Akt. 252627 Zadatak

Documents
F. No. AICTE/ PQ Dy.No. 11460/Aug/2014/103 Date: …...F. No. AICTE/ PQ Dy.No. 11460/Aug/2014/103 Date: 08.08.2014 To The Section Officer (TS-II) Department of Higher Education Ministry

F. No. AICTE/ PQ Dy.No. 11460/Aug/2014/103 Date: …...F. No. AICTE/ PQ Dy.No. 11460/Aug/2014/103 Date: 08.08.2014 To The Section Officer (TS-II) Department of Higher Education Ministry

Documents
AstraZeneca Pharmaceuticals LP IRESSA- gefitinib tablet

AstraZeneca Pharmaceuticals LP IRESSA- gefitinib tablet

Documents
ASmallMoleculeInhibitsAktthroughDirectBindingtoAkt ... · ASmallMoleculeInhibitsAktthroughDirectBindingtoAkt ... domain of Akt and blocks Akt membrane translocation. ... M. concentrations

ASmallMoleculeInhibitsAktthroughDirectBindingtoAkt ... · ASmallMoleculeInhibitsAktthroughDirectBindingtoAkt ... domain of Akt and blocks Akt membrane translocation. ... M. concentrations

Documents
Anticoagulation Knowledge Tool (AKT): Further evidence of …ecite.utas.edu.au/128294/1/AKT Italian.pdf · AKT is a self-report tool, with evidence of construct validity and reliability

Anticoagulation Knowledge Tool (AKT): Further evidence of …ecite.utas.edu.au/128294/1/AKT Italian.pdf · AKT is a self-report tool, with evidence of construct validity and reliability

Documents
The AKT - yorksandhumberdeanery.nhs.uk

The AKT - yorksandhumberdeanery.nhs.uk

Documents
Akt Notes Vts

Akt Notes Vts

Documents
Akt tl design01

Akt tl design01

Engineering
IRESSA (Gefitinib) The Journey - European Commissionec.europa.eu/research/health/pdf/event06/12052011/anne...The Trials: A Brief History IRESSA registration Japan ISEL INTEREST 2002

IRESSA (Gefitinib) The Journey - European Commissionec.europa.eu/research/health/pdf/event06/12052011/anne...The Trials: A Brief History IRESSA registration Japan ISEL INTEREST 2002

Documents
Statistics for AKT

Statistics for AKT

Documents
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to ... · of AKT-S473 (not T308) phosphorylation and AKT/mTOR inactivation. Restoration of AKT phosphorylation rescued the G1

RABL6A inhibits tumor-suppressive PP2A/AKT signaling to ... · of AKT-S473 (not T308) phosphorylation and AKT/mTOR inactivation. Restoration of AKT phosphorylation rescued the G1

Documents
Mesenchymal stem cells modified with Akt prevent ... Med. (2003)(0).pdf · Akt protein were very low in all groups, but high in Akt-MSCs. Phospho-Akt increased in all groups after

Mesenchymal stem cells modified with Akt prevent ... Med. (2003)(0).pdf · Akt protein were very low in all groups, but high in Akt-MSCs. Phospho-Akt increased in all groups after

Documents
11460.Oral Cancer Research Advances by Alexios P. Nikolakakos

11460.Oral Cancer Research Advances by Alexios P. Nikolakakos

Documents